GNLX
Genelux Corporation Common Stock
NASDAQ: GNLX · HEALTHCARE · BIOTECHNOLOGY
$2.67
+6.80% today
Updated 2026-04-30
Market cap
$114.70M
P/E ratio
—
P/S ratio
14,337.86x
EPS (TTM)
$-0.86
Dividend yield
—
52W range
$2 – $9
Volume
0.2M
Genelux Corporation Common Stock (GNLX) Financial statements
SEC filings — annual and quarterly data.
Cash flow — annual
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | $-7.22M | $-7.21M | $-6.58M | $-3.57M | $-20.27M | $-21.23M | $-25.27M |
| Capital expenditures | $1.77M | $20000.00 | $49000.00 | $49000.00 | $1.02M | $381000.00 | $1.10M |
| Depreciation | — | — | — | — | — | — | — |
| Stock-based comp | — | $5.33M | $4.27M | $2.42M | $5.20M | $6.07M | $5.87M |
| Free cash flow | $-8.99M | $-7.22M | $-6.63M | $-3.62M | $-21.30M | $-21.61M | $-26.37M |
| Investing cash flow | — | — | — | — | — | — | — |
| Financing cash flow | — | — | — | — | — | — | — |
| Dividends paid | — | — | — | — | — | — | — |
| Share repurchases | — | — | — | — | — | — | — |
| Debt repayment | — | — | — | — | — | — | — |
| Net change in cash | — | — | — | — | — | — | — |